Name:Zhu Tao (朱涛)
Born:1972.4. Hubei
Address:School of Life Science, University of Science and Technology of

China, Hefei, Anhui 230027, P. R. China
Tel:81-551-63601505
Fax:86-551-63601505
E-mail:zhut@ustc.edu.cn
EDUCATION AND RESEARCH EXPERIENCE
Tao Zhu obtained a M.D. in 1994 from Wuhan University at China and a Ph.D. in 2002 from the Institute of Molecular and Cell Biology at Singapore. His postdoctoral work was undertaken at the Johns Hopkins University in U.S.A., where He received Susan G. Komen Cancer Foundation Fellowship in 2004. Since 2007, he has been Professor of the School of Life Sciences of the University of Science and Technology of China (USTC) and Principal Investigator at theHefei National Laboratory for Physical Sciences at Microscale at China. Tao Zhu is the co-author of almost 100 peer-reviewed publications and is well-established for the international recognition of his work on cancer research. These latest focuses have produced more than 40 correspondence author work in Cell ResNature CommunPNAS, Cancer Res as well as a few intellectual properties of potential utility and value. His work received more than 4000 citations and h-index=42, i10=70.  He is the editorial board members of a number of other international journals such as Am. J. Cancer Res. He has served as a reviewer for 50 academic journals and 7 local and international granting agencies.
RESEARCH AREA
Cancer Targeted Therapeutics, Cancer Associated ncRNAs and Nanomaterials Exerted Bioactivity.
CURRENT RESEARCH PROJECTS
NSFC,MOST supported grants
REPRESENTATIVE PUBLICATIONS
1.Zhang W, Wu M, Kang Y, Chong QY, Zhang M, Qian W, Zhang X, Hu L, Zhong Y, Qian P,  Kong X, Li G, Ding K, Lobie PE*, Zhu T*(2018)Loss of Estrogen Regulated MIR135A1 at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer Cells. Cancer Res. 78(17):4915-4928
2.Tan S, Li H, Zhang W, Shao Y, Liu Y, Guan H, WU J, Kang Y, Zhao J, Yu Q, Gu Y, Ding K, Zhang M, Qian W, Zhu Y, Cai H, Chen C,  LobiePE, Zhao X*, Sun J* Zhu T*(2018) NUDT21 Negatively Regulates PSMB2 and CXXC5 by Alternative Polyadenylation and Contributes to Hepatocellular Carcinoma Suppression. Oncogene 37(35):4887-4900
3.Li G, Wu X, Qian W, Wu ZS, Cai H, Sun X, Zhang W, Tan S, Qian P, Ding K, Lu X, Zhang X, Yan H, Song H, Huang S, Wu Q, Lobie PE, Shan G, Zhu T (2016) CCAR1 5'UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance. Cell Res 26:655-73.
4.Liu Y, Qian P, Chen C, Lu X, Sun B, Zhang X, Wang L, Gao X, Li H, Chen Z, Tang J, Zhang W, Dong J, Bai R, Lobie PE, Wu Q,  Liu S, Zhang H, Zhao F, Wicha MS, Zhu T*, Zhao Y*. (2015) Gd-metallofullerenol nanomaterial nanomaterial as non-toxic cancer stem cell specific inhibitor. Nat Commun. 6,5988.
5.Lu X, Liu Y, Kong X, Lobie PE, Chen C*, Zhu T*. (2013) Nanotoxicity: A growing need for study in the endocrine system. Small 9,1654-71



Last updated: Aug. 2019   |  Copyright © Hefei National Laboratory for Physical Sciences at the Microscale  |  Top  |  Site Map